tiprankstipranks
The Fly

Karyopharm still sees 2024 revenue $140M-$160M, consensus $146.52M

Karyopharm still sees 2024 revenue $140M-$160M, consensus $146.52M

Expects existing cash, cash equivalents and investments, and revenue from XPOVIO net product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into the end of 2025.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com